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Abstract
Tumour cells show a varying susceptibility to radiation damage as a function of the current cell cycle phase. While this
sensitivity is averaged out in an unperturbed tumour due to unsynchronised cell cycle progression, external stimuli such as
radiation or drug doses can induce a resynchronisation of the cell cycle and consequently induce a collective development
of radiosensitivity in tumours. Although this effect has been regularly described in experiments it is currently not exploited
in clinical practice and thus a large potential for optimisation is missed. We present an agent-based model for three-
dimensional tumour spheroid growth which has been combined with an irradiation damage and kinetics model. We predict
the dynamic response of the overall tumour radiosensitivity to delivered radiation doses and describe corresponding time
windows of increased or decreased radiation sensitivity. The degree of cell cycle resynchronisation in response to radiation
delivery was identified as a main determinant of the transient periods of low and high radiosensitivity enhancement. A
range of selected clinical fractionation schemes is examined and new triggered schedules are tested which aim to maximise
the effect of the radiation-induced sensitivity enhancement. We find that the cell cycle resynchronisation can yield a strong
increase in therapy effectiveness, if employed correctly. While the individual timing of sensitive periods will depend on the
exact cell and radiation types, enhancement is a universal effect which is present in every tumour and accordingly should be
the target of experimental investigation. Experimental observables which can be assessed non-invasively and with high
spatio-temporal resolution have to be connected to the radiosensitivity enhancement in order to allow for a possible
tumour-specific design of highly efficient treatment schedules based on induced cell cycle synchronisation.
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Introduction
Tumours are complex dynamic objects which can adapt to
changes in their environmental conditions and accordingly react to
treatments such as radiotherapy. Withers was one of the first to
note that the now common scheduling of radiotherapy in fractions
is efficient, because it exploits these dynamic intra-tumoural
effects. He identified and described the four ‘‘R’’s of radiotherapy
which today form the basis of clinical practice: redistribution, re-
oxygenation, repair and regrowth. After the use of fractionation
schemes became common in clinical treatment, further investiga-
tion led to the conclusion that standardised protocols might not be
the optimal solution for each patient, but rather that altered
individual fractionation schemes should be considered [1]. In
particular the cell cycle redistribution during radiotherapy has
been studied early [2,3] and regularly ever since in a variety of
experimental systems [4]. Nevertheless, today cell cycle effects are
not routinely included in treatment planning and are disregarded
as ‘‘unusable’’ even though the advent of modern imaging
technologies has delivered a variety of suitable tools which could
assess not only oxygenation but also cell cycle status in vivo [5,6].
Cancer therapy is clearly advancing in the direction of highly
individualised, tailored treatment protocols as a result of a range of
new technological developments in radiation delivery [7] and
monitoring [8,9]. In order to find optimal protocols, a detailed
understanding of the treatment effects on the target system is
necessary. This is where mathematical and computational models
are needed in order to describe and understand the complex
interdependencies of the tumour. They open up the possibility to
also screen unusual treatment approaches for efficient strategies.
Accordingly, over the last decade, a variety of models have been
designed for the purpose of treatment planning, be it for
radiotherapy [10,11], chemotherapy [12], combined treatment
approaches or others aspects of tumour growth and therapy [13–
15].
One particularly successful example of therapy optimisation is
the description and use of circadian timings in cancer therapy
[16,17]. Especially for chemotherapy the careful timing of drug
delivery in conjunction with the natural cell cycle dynamics has led
to interesting predictions [15,18,19] and an measurable increase in
clinical efficiency both in cancer-therapy and in the treatment of
non-cancer diseases [20–22]. Also with respect to DNA repair and
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cancer therapy [23]. However few models have specifically
addressed the effect of cell cycle redistribution in conjunction
with cell-cycle specific radiosensitivity [24] and most of these rely
on an abstract representation of the tumour cell population. In
comparison to a previous single cell-based model by the authors
[25] the new model relies exclusively on measurable cell
parameters in order to allow for a more direct comparison to
experiments. It has been based on the linear-quadratic model for
radiation survival and introduces a range of observables to
quantitatively describe the synchronisation and sensitivity changes
within the tumour spheroid. These qualitative changes and
extensions were necessary in order to allow for the study of
realistic fractionation schemes as well as alternative radiation
delivery timings. Tumour spheroids have been chosen as model
system for radiation reactions as they allow for a straightforward
testing of predictions in vitro, while retaining a considerable degree
of realism when compared to flask cultures [26]. It is to be
expected that the effects of synchronisation observed in tumour
spheroids are not completely lost in in vivo tumours and are worth
being a target of further research for that reason.
Within the investigation the focus rests on the redistribution of
cells within the cycle phases which occurs as a result of irradiation
during treatment. Using a three-dimensional, agent-based model
of microtumour growth, we will show its implications for the
fractionation of irradiation during clinical treatment schedules. It
allows us to demonstrate that an individualised treatment plan,
which incorporates cell cycle redistribution effects, can yield a
better outcome than typical standardised treatment schedules. The
predictions of our model system can thus be used as a guideline for
subsequent in vitro experiments and, after in vivo study and
validation, ultimately be incorporated into clinical trial settings.
Methods
Agent-based tumour spheroid growth
A three-dimensional single-cell based model is developed in
order to study the growth of tumour nodules and their reaction to
therapeutic approaches. The main parameters are listed in table 1.
It has to be stressed that all parameters used within the simulation
are physically accessible and thus can be obtained from
experimental measurements. Accordingly the simulation can be
tailored to model a specific cell line in conjunction with joint
experimental investigations. However the observed effects are of a
universal nature, meaning that they are largely insensitive to
variation of parameters, as has been tested in the simulation.
Hence the choice of parameters is exemplary for a wide
physiological range of cells and does not aim to reflect one
specific cell line. Technically the present model is developed in
C++ code on the framework of the Voronoi-tessellation of
biological tissue [27,28]. A validation of the employed tumour
growth model is provided in reference [25] and in the supporting
figure S3.
The use of a three-dimensional spheroid model is of importance
in order to obtain a system which comprises a range of features
that are present in real tissues and which cannot be adequately
described using two-dimensional models [29,30]. Accordingly it
has been demonstrated experimentally that the treatment reaction
of cells in three dimensional structures such as multilayers,
spheroids or xenograft tumours can differ strongly from the
reaction in a monolayer [31–34]. This is to a large extent an effect
of the cell interaction within a tissue and the specific spatially and
temporally heterogeneous cell cycle distribution which will arise in
a tumour spheroid [35,36]. Realistic nutrient gradients, as they
develop in response to diffusion through a breathing tissue, will
only be found in such three dimensional cell arrangements.
Overall a macroscopic tumour in vivo (with a diameter in the
order of centimetre) is comprised of small microscopic sub-
volumes of about 500 mm diameter which form in between
capillaries. Each of these microtumour regions will consist of an
outer proliferating rim, an intermediate mostly quiescent region
and an inner necrotic region as a result of the limited nutrient
diffusion range. Due to the structure of vessels these regions will
usually be elongated and stretch out between capillaries but also
regular patterns of nutrient support have been observed in
tumours [37]. Our model spheroid directly corresponds to one
such microregion or tumour nodule [36], and can also serve as a
model for the reaction of a larger tumour volume as a result of its
functional and histological correspondence to a microtumour
region [38].
Cell representation and cycle. The spatial arrangement of
cells in a tissue is represented using a Voronoi-Delaunay approach
[27,28]. Interaction between cells is adhesive-repulsive and
performed using the Johnson-Kendal-Roberts model [39] as
described in detail in [25].
Cell cycle progression is assumed to depend on external
conditions, specifically the local nutrient availability (glucose
concentration in the medium) and interaction with neighbouring
cells (integral pressure) as shown in figure 1. Within the model a
complete local depletion of glucose will trigger cell death via a fast
necrotic process [40], while an integral pressure on the cell above
200 Pa will induce quiescence at the G1/S-checkpoint as a result
of contact inhibition [35,41], which lasts until the pressure falls
below the threshold value.
The spheroids used for irradiation within the scope of this
investigation are grown from a small number of 10 virtual seeder
cells which resemble cells of the EMT6 line in in vitro cultures [42]
(matching the typical cell cycle phase-lengths, interaction param-
eters, response to starvation and so forth, see table 1 and [25]).
Nutrient modelling. Availability of glucose and oxygen is
modelled using a cubic reaction diffusion solver system of 1.4 mm
edge length. Nutrient conditions in regions of the system which are
not occupied by cells are adapted to match in vitro values from [43]
Author Summary
The sensitivity of a cell to a dose of radiation is largely
affected by its current position within the cell cycle. While
under normal circumstances progression through the cell
cycle will be asynchronous in a tumour mass, external
influences such as chemo- or radiotherapy can induce a
synchronisation. Such a common progression of the inner
clock of the cancer cells results in the critical dependence
on the effectiveness of any drug or radiation dose on a
suitable timing for its administration. We analyse the exact
evolution of the radiosensitivity of a sample tumour
spheroid in a computer model, which enables us to
predict time windows of decreased or increased radiosen-
sitivity. Fractionated radiotherapy schedules can be
tailored in order to avoid periods of high resistance and
exploit the induced radiosensitivity for an increase in
therapy efficiency. We show that the cell cycle effects can
drastically alter the outcome of fractionated irradiation
schedules in a spheroid cell system. By using the correct
observables and continuous monitoring, the cell cycle
sensitivity effects have the potential to be integrated into
treatment planing of the future and thus to be employed
for a better outcome in clinical cancer therapies.
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concentrations with 5 mM glucose and 0.13 mM oxygen when in
vivo tumour nodule growth is studied. Cells consume nutrients
using a cell cycle phase-specific uptake rate and accordingly act as
sinks in the reaction diffusion solver [44,45].
Model for cell reactions to irradiation
The total amount of cell death in response to a radiation dose
matches experimental measurements, as the linear quadratic
model for single cell survival with measured parameters is
employed. In response to irradiation with the dose D (defined in
Gy) cells obtain a cell cycle phase-dependent survival probability Sp
from the linear quadratic model [46]:
Sp~e
{(apDzbpD2) ð1Þ
As physiological example ap and bp values of V79 hamster cells
which were subjected to x-rays by Sinclair [2] are employed
(supporting figure S2 and table 1). It has been repeatedly reported
that quiescent cells exhibit an increased resistance to radiation
damage [47–50]. This fact is incorporated into the model by using
a quiescence resistance factor (QRF=1.5) to scale down the
effective radiation dose which quiescent cells experience. Thus,
within this assumption, quiescent cells use the measured LQ-
parameters of G1 cells but with reduced dose.
Once committed to the death path, a cell can either be killed on
a fast timescale (probability ‘‘acute chance’’ AC) or after delay on
a slow timescale (with probability 1{AC) as shown in figure 1.
The fast process corresponds to a relatively acute, direct
commitment to cell death via apoptosis or necrosis in response
to heavy DNA damage (e.g. clustered lesions) and accordingly a
rather low duration for cell death was chosen with an average of
12 h [51–53]. The slow process corresponds to a prolonged
inability to pass the G2/M checkpoint which will lead to the pile-
up of cells in the G2-phase after irradiation and eventually leads to
cell death e.g. via mitotic catastrophe or a loss in the so called
‘‘race between repair and cell death’’ [54,55]. Both is represented
as failure at the G2/M checkpoint and progression to cell death
with a ‘‘mitotic mismatch’’-rate MM.
While this model drastically simplifies the multitude of
mechanisms of radiation-induced cell death [56], the overall
amount of cell death observed will be in agreement with
experimental measurements within the LQ-model. The inclusion
of a fast and slow damage timescale increases the matching of the
predicted cell cycle response to experimental measurements [57].
Damage repair is not considered in detail within the model as it
will be phenomenologically contained within the measured LQ-
survival. Furthermore the typical radiation delivery interval within
the simulations will be large enough in order to assume largely
independent irradiation events as the majority of remaining
damage will have been repaired in the inter-fraction time [58,59].
Measuring radiosensitivity and tumour burden
In order to assess the radiosensitivity of the tumour spheroid, we
use the ratio of the virtual total survival observed in our simulation
at the time of interest and a baseline survival which is expected for
the tumour cells under consideration. The expected survival Sexp is
defined as the average of the survival probabilities, where each cell
cycle phase specific survival probability from the LQ-model Sp is
weighted with the average duration of the corresponding phase-
length tp and normalised using the total average cycle time T:
Sexp~
1
T
X
p~fG1,S,G2,Mg
Sptp ð2Þ
This baseline survival reflects the typical survival of an exponen-
tially growing tumour spheroid without quiescent sub-population
and with uniform distribution of the cells proportional to the cycle
phase-lengths. Consequently it should correspond to the expected
survival within fully active microregions of a macroscopic tumour.
However, within the scope of this work it will be only applied in
the context of tumour spheroids.
The observed cell survival Sobs can be obtained at any time by
virtual simulation of the impact of a dose of radiation, without
Table 1. Selection of parameters for growth and irradiation used within the simulation.
Parameter Value Remark
rmin/rmax 7.94/10 mm minimum and maximum cell radius [86]
tG1,tS,tG2,tM 8 h, 6 h, 4.5 h, 1 h average cell cycle phase duration [43,87]
tN,tA 24 h, 12 h average necrosis and apoptosis duration [40,51,87]
s 0.3 standard deviation of phaselength normal distribution, fit
g 0:6tp cut-off for phaselength normal distribution, fit
Pcrit 200 Pa critical cell pressure for quiescence; [88], growth fit
CGl 0 mM glucose concentration for necrosis; growth fit
AC 0.66 chance for acute, fast radiation-induced cell death; [57] fit
MM 10{3min{1 effective rate of slow cell death at G2/M checkpoint; [57] fit
QRF 1.5 dose-reduction factor of quiescent cells [47,49]
aG1,bG1 0.351, 0.04 LQ-parameters for G1 cells (and G0 with QRF) [2][46]
aS,bS 0.1235, 0.0285 LQ-parameters for S-phase [2][46]
aM=G2,bM=G2 0.793, 0 LQ-parameters for M- and G2-phase [2][46]
Further parameters and sources for the handling of cell interaction, nutrient diffusion and consumption can be found in [25] and [28]. The model aims to describe a
generic tumour so the analysis does not rely on data for one specific tumour cell line only but on parameters which are within the established physiological range.
Parameters for glucose and oxygen diffusion from [89][90][91] and according cell uptake rates from [44,86].
doi:10.1371/journal.pcbi.1003295.t001
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fraction of surviving cells yields the observed survival:
Sobs~
cviable
cdeadzcviable
ð3Þ
Consequently we define the enhancement E as the ratio of
expected and observed survival:
E~
Sexp
Sobs
~
1=T
P
p~½G1,S,G2,M  Sptp
cviable=(cdeadzcviable)
ð4Þ
An enhancement larger than one reflects a tumour in a state of
increased sensitivity to radiation, while a lower enhancement
reflects a resistant state, as is the case for a tumour which contains
a large quiescent population.
As a measure of treatment success we use the tumour burden,
which is defined as the integral of the total number of cells in the
tumour over a time of interest (area under the curve). A typical
unit for this observable is 106 cell-days. Further radiobiological
observables like the mitotic index (MI) and S-phase fraction (SPF)
are directly accessible from the cell cycle distribution of the agent-
based model at all times. They can be used to predict
radiosensitivity directly as in [60] and can be compared to
experimental measurements.
Measurement of cell phase-angles and tumour
synchronicity
The cell phase-angle h is used to measure the relative progression
of an individual cell through its cell cycle, independent of functional
cell cycle phases. h is defined as the ratio of total time spent in the
active cell cycle phases t (cells which enter quiescence will thus not
advancetheir phase-angle) andtheindividualtotalcell cycle time T:
h~
t
T
ð5Þ
Sincethecell cycletimes aredrawn from a normaldistribution(with
a maximum variation) individually for every cell and cycle phase,
two cells can have an identical phase-angle h while their functional
cell cycle phase is not identical.
Using the phase-angle we define the orderedness O(t) of the
tumour cell population, by calculation of the Shannon entropy of
the system. The probability mass function p(t) will be obtained by
sorting all cells of the tumour into N bins according to their cell
phase-angle h. Thus we can calculate the Shannon entropy of the
tumour system
H(t)~
X N
i~1
pi(t)log2
1
pi(t)
  
ð6Þ
and use its maximum Hmax~log2 (N) to define the orderedness
of the population as
O(t)~
Hmax{H(t)
Hmax
: ð7Þ
The entropy and orderedness of the system are well behaved,
so that it is possible to use a small number of bins N for
grouping. One such arrangement is the ordering of cells by
functional cell cycle phase or cell DNA content, which are both
easily assessed experimentally in in vitro settings or in vivo from
biopsies.
The orderedness O(t) of the system will approach 1 for
synchronous populations and 0 for populations which are
uniformly distributed in the cell cycle.
Figure 1. Cell cycle, response to environmental factors and radiation as implemented in the model. Black circles mark cell cycle
checkpoints. Cells can enter and leave quiescence in response to the local pressure at the G1/S checkpoint. If the critical conditions improve, cells re-
enter the active cell cycle by passing the restriction point. Growing cells double their volume during G1 and G2 phase, so that the cell volume is
conserved in mitosis. At the G2/M checkpoint cells will be halted if their DNA is damaged. This arrest is subject to a chance of failure, so that, with a
defined probability, cells can pass into mitosis even though their DNA is damaged. Cell death in response to critical nutrient deprivation is possiblea t
any time via necrosis. In response to irradiation, individual cells will commit to cell death if a random value exceeds their cell-cycle specific survival
chance from the linear-quadratic model in equation 1. Cell death in response to radiation is realised either via a fast, acute commitment to cell death
or by prolonged fixation at the G2/M checkpoint which will lead to cell death via apoptosis as a result of mitotic catastrophe or other fatal errors.
doi:10.1371/journal.pcbi.1003295.g001
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Growth and cycle desynchronisation
In silico tumour spheroids were grown in a standardised protocol
from 10 tumour seeder cells using the parameters in table 1. The
seeder cells were allowed to grow for 14 days and formed
microtumours of about 105 cells with a typical diameter of
700 mm. An initial exponential growth phase was followed by a
subsequent growth retardation by induced quiescence and
necrosis. Treatment of the spheroids started at day 14.
The fully grown microtumours incorporated all typical histo-
logical regions which are of importance for the radiation response.
A large, stable quiescent cell population was present, which could
quickly respond to radiation-induced changes in the tumour
environment (figure 2). Due to dissolution of necrotic cells a hollow
core formed in the tumour spheroid before a treatment plan was
started (figure 2 and supporting figure S3
The synchronicity of the tumour cell population steadily
decreased over time as the cell cycle progression was desynchro-
nised by the normal distribution of cell cycle times. This decrease
is visible as smoothing of the oscillation in the cell cycle
distribution in figure 2A and directly via the decrease in
orderedness as shown in supporting figure S1. Another major
contribution to the desynchronisation was the entry of cells into
quiescence and subsequent re-entry into the active cycle.
Irradiation reaction, cycle redistribution and
enhancement
After homogeneous irradiation of the tumour spheroid with 4
Gy a large fraction of cells committed to cell death (figure 2).
However, irradiation of the tumour also led to its subsequent
reactivation. Through the clearing of dead cells the pressure and
nutrient situation for surviving cells improved considerably, which
triggered a fast re-entry of previously quiescent cells into the active
cycle (figure 2), as has been observed experimentally [61,62]. This
radiation-induced regrowth was exponential as almost all clono-
genic cells in the spheroid were dividing again.
Radiation led to a redistribution and synchronisation of the cell
cycle progression as it killed predominantly cells in sensitive phases
of the cycle. The observed redistribution and subsequent evolution
of the cell cycle distribution corresponded well to experimental
observations [57] (figure 3). A G2-block of cell cycle progression
was observed, where DNA damaged cells gathered at the G2/M
checkpoint. Thus the ratio of cells in G1 to cells in G2 was
transiently inverted in response to a radiation dose (figure 2). Best
agreement was achieved when a high degree of fast, acute and a
lower level of slow cell death e.g. through mitotic catastrophe were
used for the radiation death dynamics. The timescale but not the
quality of the dynamic reaction is subject to variations by cell- and
radiation type as can be seen in [58] for Chinese hamster V79 lung
cells or [63] for SiHa xenograft tumours.
Due to the higher radioresistance of quiescent cells, immediately
after irradiation the relative fraction of quiescent cells among all
viable was temporarily increased. The subsequent re-entry of
quiescent cells into the active cycle was largely synchronised at the
G1/S checkpoint (figure 2).
The synchronisation of the cell cycle progression led to
collective oscillations of radiosensitivity in the tumour (figure 3).
The enhancement in the tumour exhibits a transient, two-peaked
reaction to irradiation. The observed loss of sensitivity for a
quiescent tumour and the subsequent gain in sensitivity after
irradiation increased with dose. While a quiescent tumour was
only half as sensitive to a dose of 8 Gy as its exponentially growing
counterpart, after irradiation its sensitivity increased more than
twofold. Accordingly, one goal in experimental scheduling can be
to design a radiation delivery which is optimised to use these
recurring periods of transient sensitivity and avoid dose delivery
during times of radiation resistance.
Comparison of clinical irradiation protocols
Clinically a large integral dose will be applied in multiple
fractions in order to sterilize a tumour or reduce its size. Dose
delivery will be fractionated in order to limit side effects in
surrounding tissue and exploit the initially mentioned effects that
the fractionated delivery has on the tumour [1]. The timing of
dose application is typically chosen such as to provide a balance
between practical restrictions such as clinical workload, curative
effect and side effects.
The standard clinical radiotherapy protocol is the repeated
application of doses of 2 Gy each in daily fractions which will be
administered over a prolonged time until an integral dose of
typically 60 Gy is reached. Treatment is often paused during
weekends to allow for tissue regeneration and re-oxygenation, but
also for reasons of clinical workload. Common alternative
fractionation schedules include hyperfractionation e.g. with the
delivery of 2 smaller fractions every 12 hours or hypofractionation
with the delivery of higher single doses and a shorter total
treatment time [46,64,65]. Typically a similar integral dose is used
(table 2). Alternative schedules which employ very high single
doses as in Stereotactic Body Radiation Therapy [66] or
oligofractionation [67] will no be part of the investigation, as they
would most likely exceed the validity of the linear-quadratic
model.
Figure 4 provides an overview of the effects of selected
fractionation schemes from table 2 when applied to the model
tumour. In general a high degree of regrowth in response to
irradiation was observed in silico. Reactivated cells repopulated the
tumour and due to their unlimited replicative potential lead to a
quick reformation of the spheroid. This was true even when only a
very small number of cells was left alive. A typical integral dose of
60 Gy thus did not fully sterilize the model tumour, even when
applied in a short amount of time such as in a hypofractionated
schedule. This is in agreement with experimental observations on
multicellular tumour spheroids in vitro, where a much more rapid
growth of spheroid cells is observed than for cells in an in vivo
setting [58].
In terms of a reduction of the tumour burden, the high dose-
per-time schedules all performed better. In general they allowed
less regrowth of the tumour to occur due to the shortened
treatment time. Furthermore they benefited from the quadratic
term in the dose-survival relation of the LQ-model eq. 1 due to the
high single-doses used.
Longer treatment pauses, as in the conventional, ‘‘un-acceler-
ated’’ schedules, had a significant negative effect on the tumour
control. Each pause allowed for an unchecked period of regrowth
within the tumour, which was not cancelled out, as the integral
dose was kept constant. Treatment pauses can make all the
difference between the achievement of a steady reduction in
tumour load, or a failure to keep the tumour in check (figure 4).
Schedules which employed a low dose per fraction (such as
hyperfractionation) performed better than schedules which deliv-
ered the same dose per time in medium-sized single fractions. This
is not to be expected, as the quadratic survival term in the LQ-
model will yield a lower survival for larger doses. The reason for
this observation is the timing of the radiation delivery in
conjunction with the development of tumour radiosensitivity
(figure 4). While the conventional radiation schedule delivered
follow-up doses at a time of low tumour radiosensitivity, within the
Cell Cycle Synchronisation Effects in Radiotherapy
PLOS Computational Biology | www.ploscompbiol.org 5 November 2013 | Volume 9 | Issue 11 | e1003295Figure 2. Reaction of a tumour spheroid to irradiation. Panel A shows the cell phase distribution during growth of a tumour spheroid and in
response to irradiation with 4 Gy. B Redistribution in response to 4 Gy and subsequent dynamics in the fraction of viable cells. C Lateral cut through a
tumour spheroid during different phases of growth and irradiation. An initial small number of seeder cells will form a solid tumour spheroid, where
cells in high-density regions go into quiescence. Nutrient deprivation and subsequent dissolution of necrotic cells lead to the formation of a hollow
core. After irradiation with 4 Gy a majority of cells will be apoptotic, which leads to a reactivation of quiescent cells. Consequently a fast regrowth and
the re-establishment of the necrotic core are observed. Cells are visualised as spheres but are handled as polyhedra while in contact within the 3D
Delaunay triangulation used in the model [25]. Cells in G1, S or G2-phase in cyan, mitotic cells in red, quiescent cells in grey, necrotic cells in brown
and apoptotic cells in green.
doi:10.1371/journal.pcbi.1003295.g002
Figure 3. Cell phase redistribution and according change in overall radiosensitivity in response to irradiation. A Comparison of the
cell cycle redistribution in silico after irradiation with 2 Gy and in vitro for LN229 cells from [57]. B Effect of a single radiation dose on post-irradiation
sensitivity of the tumour. Depending on the applied dose the effects of a growing quiescent, radioresistant sub-population are increasing, as can be
seen in the development of the enhancement during the tumour growth up to the irradiation at time zero. After irradiation an initial period of
increased radioresistance is followed by transient maxima in radiosensitivity which are suitable for targeting by subsequent fractions. Oscillations of
enhancement are dampened by the entry of cells into quiescence after regrowth and by the normal distribution of cell cycle phaselengths.
doi:10.1371/journal.pcbi.1003295.g003
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time of high radiosensitivity.
Dose delivery within the conventional, accelerated conventional
or split course treatment occurred in intervals, which failed to
induce a persistent high enhancement in the tumour. Hyper-
fractionated schedules in contrast succeeded at keeping the
enhancement in the tumour at a steady high level, which was
especially true for the accelerated hyperfractionation schedule.
Effectively the hyperfractionated schedule suppressed the refor-
mation of a radioresistant quiescent subpopulation. Although it
allowed the tumour to grow exponentially at all times, the frequent
delivery of doses kept the growth in check.
Even so CHART used lower single doses it was able to achieve
a high tumour control at an overall lower integral dose. However,
the dose per time interval which is applied in CHART treatment is
very high with 4.5 Gy/24 h, thus possibly increasing side effects of
the treatment. Considering the fast repair of sublethal damage in
most cells, CHART would however allow for repair of most
damage in surrounding tissue with a delivery interval of 8 hours.
CHART-fractionation kept the enhancement of the tumour for
follow-up doses steadily above a level of one, thus achieving a
moderate increase in effectivity (figure 4).
Systematic variation of dose rate
For a better comparison of the effects of delivery timing, it is
useful to systematically compare schedules which apply the same
integral dose over the same time, but with a systematically varied
dose per time interval. We thus investigated how the varied
fractionation of a typical constant dose per time of 2 Gy per day
would influence the outcome of a radiotherapy regimen (figure 5).
The tumour burden was significantly different and best perfor-
mance was observed for delivery intervals of 30, 36 and 48 hours
(figure 5).
Larger single fractions, as for a delivery interval of 48 h, have
the advantage of inducing a higher amount of cell death when
compared to the combination of multiple smaller doses (due to the
quadratic term in the LQ model). While it is thus not surprising
that a run with the largest single doses of 4 Gy showed a good
performance, it is interesting that this performance was closely
matched by a run with single doses of only 2.5 Gy. Treatment with
intermediate single doses of 3.5 Gy performed significantly worse
than with doses of 2.5 Gy, which demonstrates that the quadratic
dose-effect alone does not determine the success of the treatment.
Instead the success of the 2.5 Gy schedule can be explained by the
good match between the fractionation timing an the tumour
enhancement development (figure 5). A negative timing effect is
present in the 3.5 Gy schedule when compared to the 4 Gy
schedule (figure 5). The enhancement effects cancel out the
advantage of the larger single dose due to LQ-survival.
Tumour sterilisation
Repeated delivery of doses of 3 Gy with varying inter-fraction
time were applied until the in silico tumour was fully sterilised
(figure 5). Due to the radiation-induced reactivation and regrowth,
longer inter-fraction times will be associated with a higher amount
of tumour regrowth, so that a linear dependency of total dose
necessary for sterilisation and fractionation interval might be
expected, which turns out to be wrong. Instead the required
number of fractions for sterilisation exhibits a minimum at
fractionation intervals of 500–700 minutes.
Analysing the development of enhancement during the contin-
ued radiation delivery reveals that the nature of the fractionation
curve can be explained by the relation between irradiation interval
and enhancement development (see also supporting figure S6).
Low fractionation interval times of 100 to 300 minutes are
inefficient, because the tumour is still in a region of low
enhancement when it receives a follow-up dose. A follow-up
interval of 400 minutes already allows for a gain in enhancement
before the next dose is applied. This gain in enhancement is so
large that it counterbalances the effect of tumour regrowth for
treatment intervals from 400 to 1000 minutes. If a larger interval is
used, the number of fractions needed to sterilise the tumour grows
drastically as the follow-up irradiation coincides with a minimum
in enhancement at the 1200 minutes interval.
For even larger fractionation intervals a lower integral dose will
be sufficient for sterilisation even though a higher total regrowth
time is allowed. The coincidence of rising triggered enhancement
and follow-up radiation dose delivery leads to the local minimum
in fractions needed between 1300 and 1600 minutes fractionation
interval time.
Triggered and automatic enhancement-based irradiation
protocols
A range of tailored radiation protocols was designed in order to
exploit the induced dynamic changes of radiosensitivity in the
tumour and deliver radiation at timepoints of high enhancement
(figure 6). One strategy was to divide the dose delivery into trigger-
doses and subsequent effector-doses. Effector doses were delivered
with a constant time-shift after the trigger-doses, which corre-
sponded to the peak-timing in enhancement which was observed
after administration of a single dose (figure 3). After each
combined trigger and effector dose block, irradiation was paused
in order to achieve an overall constant dose per time interval of 2
Gy/24 h.
In general, protocols were successful which used a smaller
trigger dose in combination with a larger follow-up dose. The
initial trigger dose induced a synchronisation in the tumour and
increased enhancement. The large following effector dose would
then be delivered to a sensitive tumour. Very small trigger doses
below 1 Gy induced only a partial resynchronisation of the
population and thus lead to an overall poor performance when
employed in triggered schedules.
Surprisingly the protocol which delivers a trigger dose of 2 Gy
followed by an effector dose of 4 Gy was able to cancel out the
Table 2. Overview of selected clinical fractionation schemes
that have been tested in the simulation.
Schedule Total dose Dose/Fraction Fractions
[Gy] [Gy] per day/per week
Conventional 60 2 1/5
Accelerated Conv. 60 2 1/7
Hypofractionated 60 4 1/5
Accelerated Hypo. 60 4 1/7
Hyperfractionated 60 1 2/10
Accelerated Hyper. 60 1 2/14
CHART 54 1.5 3/21
Split course 60 2 1/5
Concomittant boost 60 2 1–2/5–10
For better comparison of effects the integral dose for all runs has been chosen
to be 60 Gy (except for CHART treatment with 54 Gy). In order to test the results
of hypo- and hyperfractionation, extreme cases with doubled or halved doses
per fraction where chosen. A visualisation of the according fractionation
timings is presented in figure 4.
doi:10.1371/journal.pcbi.1003295.t002
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between an effector dose and the next trigger-effector
combination. Except for the fact that this protocol employs
large single doses of 4 Gy (which might increase side-effects),
it is especially interesting for a combination with adjuvant
approaches which could reduce regrowth during the treat-
ment pauses and thus could further improve the outcome
substantially.
All triggered treatment protocols resulted in an increase in
tumour reduction when compared to the standard accelerated
conventional or accelerated hyperfractionated schedule. However,
the simple altered protocol of constant 2.5 Gy/30 h was still the
most successful protocol in terms of overall tumour burden
reduction (figure 6). In this case the timing of the follow-up dose by
chance persistently matched the peak in triggered sensitivity over
the whole treatment time (figure 5).
Figure 4. Effect of different treatment schedules on the tumour spheroid. A Visualisation of the radiation timing in selected fractionation
schedules is provided in table 2. Marker size is indicative of fraction dose. At time zero the tumour is seeded with a small number of cells. Treatment
schedules were started at day 14 of tumour growth, when a fully structured tumour spheroid had developed. B–C Comparison of total tumour size
during high dose-per-time and low dose-per-time scheduling (left .2 Gy/24 h, right #2 Gy/24 h ). D–E Development of enhancement during
selected schedules can explain the different performance of the schedules (radiation times marked with circles).
doi:10.1371/journal.pcbi.1003295.g004
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achieved the desired effect of inducing and exploiting a state of
high radiosensitivity, the trigger-effector block of the same timing
would not always prove to be right at later times during the
irradiation regimen (figure 6). In many cases a fixed timing for the
trigger-effector block would lead to the delivery of the effector dose
at times of lowered radiosensitivity, once the tumour composition
had changed during treatment. The time for the tumour to settle
into a steady state in terms of enhancement reaction was larger
than 48 hours and therefore larger than the typical inter-fraction
Figure 5. Systematic investigation of the performance of different scheduling schemes. A Comparison of total tumour size in response to
altered scheduling of the standard dose of 2 Gy/24 h. While high-dose fractions have an advantage because of the quadratic term in the LQ radiation
response, they are outperformed by some lower-dose schemes due to a better timing of the treatment to the tumour radiosensitivity development
(compare e.g. 2 Gy/24 h and 2.5 Gy/30 h). B Overall performance of varied dose distribution measured as tumour burden for the time period from
treatment begin at day 14 to day 44. C–D Timing of fractions in relation to the enhancement development for selected runs can explain the different
schedule performance. E–F Repeated delivery of doses of 3 Gy with different delivery intervals until full sterilisation is achieved. The number of
fractions required for sterilisation depends non-linearly on the inter-fraction time. This complex dependency is a result of the enhancement
development within the tumour as discussed in the text and further illustrated in figure S6.
doi:10.1371/journal.pcbi.1003295.g005
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able to maintain a proper trigger-effector dose timing for a part of
the treatment regimen before changes in the tumour composition
caused the timing to fail.
In many cases after application of the effector dose, a further
strong peak in enhancement developed (figure 6). In principle, this
allows for an increasing ‘‘stacking’’ of trigger and effector doses up
to the case of continuous delivery at the next triggered sensitivity
peak. Protocols with a combination of 3 consecutive well-timed
doses in a constant block however did not prove to be effective, as
delivery suffered strongly from the shift of the enhancement
response during treatment.
As the enhancement response timing changes during the course
of a prolonged treatment regimen, the targeting of the optimal
enhancement point is only possible with permanent recalculation
of the timing and, thus, can usually not be achieved with a fixed
schedule. In order to exploit the build-up of radiosensitivity,
triggering algorithms were tested which automatically delivered a
follow-up dose at times of high enhancement (figure 6). A peak in
enhancement was detected either by linear regression of the
enhancement in a time window of interest, or in the simplest case
by absence of an increasing enhancement value within a time
window of tmin. Once a peak was detected, radiation was delivered
if the resulting dose was above a minimum of Dmin. The dose was
calculated in order to reach a constant dose per time interval of 2
Gy/24 h. For comparison a manually optimised schedule was
tested, where a dose was always delivered exactly at the suitable
enhancement peak.
The simple automatic triggering algorithm performed signifi-
cantly better than conventional schedules, if the delivery of low
doses was allowed by setting Dmin to 1 Gy. As a result of the small
time interval which was necessary in order to identify each
enhancement peak, the automatic triggering performs slightly
worse than a manual optimised treatment schedule (figure 6).
While this automatic dose delivery could achieve a very good
performance in terms of tumour reduction, it was still slightly
inferior to the most successful schedule of 2.5 Gy/30 h. This
inferior performance was due to the fact that the triggering
algorithms and also manual scheduling performed only a local
optimisation, triggering at the next suitable maximum of
enhancement. However, an effective overall treatment schedule
design requires a global optimisation, which cannot be achieved
with algorithms that only take into account the following sensitivity
maximum.
Discussion
We employed an agent-based model in order to study the
reaction of a microtumour to radiotherapy with special emphasis
on the cell cycle distribution, synchronicity changes and the
subsequent development of the overall radiosensitivity. The two-
peaked increase in radiosensitivity which followed a dose of
irradiation (figure 3) was used as a guideline for optimal irradiation
timing in fractionated treatment regimens. The simple use of
experimentally determined cell cycle-specific radiosensitivity,
combined with a simple survival model, thus predicts optimisation
possibilities in radiation delivery. The predicted results must must
be validated or refuted in either an in vitro or an in vivo system.
The total possible gain or loss in efficiency of a treatment
schedule due to cell cycle effects is immense. This becomes evident
when the best and worst possible outcome for irradiation with 2
Gy are compared with according cell survival of 30% or 70%,
depending on the cycle phase. For a treatment regimen with only
20 fractions this will yield a worst-case difference of a factor
G~0:320=0:720&23000000. Even if this value represents an
extreme case, most regimens will actually feature more than 20
fractions so that even small changes in survival based on cell cycle-
dynamic can significantly alter the overall chances of tumour
control.
In general the suppression of quiescent cells achieved by most
hyperfractionated schedules is beneficial on one hand, as it will
avoid quiescent radio-resistance. On the other hand, it will fully
activate the growth potential of the tumour and thus allow for an
exponential regrowth. The latter effect is especially devastating
when combined with longer treatment pauses. An efficient
combination with regrowth-cancelling adjuvant treatments would
be needed, which could be combined with treatment protocols
that make use of large inter-fraction pauses. Another viable option
for combination of adjuvant chemotherapy and radiotherapy is the
use of drugs which can prepare the tumour into a radiobiologically
sensitive state [68,69]. This can be achieved by the well-timed
administration of drugs which have a cell-cycle synchronising
effect, such as hydroxyurea [70,71]. Within the simulation
appropriate radio-chemo-schedules were tested and able to
achieve significant enhancements in treatment outcome, especially
when used in conjunction with high single doses (results not
shown).
The observed cell cycle effects and reoxygenation of the tumour
spheroid are also of interest for modern heavy-ion irradiation
whenever spread out Bragg peaks are used that show a mixed-
LET composition [72]. Especially in treatments which employ
large single doses, such as in relativistic plateau proton-radiosur-
gery [73] or Stereotactic Body Radiation Therapy [66,74], the cell
cycle effects could be considerable and at the same time their
dynamics can be easily estimated. Also in modern oligofractio-
nated schedules which employ very high fractions [67], cell cycle
effects could accordingly affect the treatment efficiency and could
be possibly used quite actively. In order to study these effects in
silico new radiation damage models need to be considered, which
accurately describe radiation effects also in the range of very high
doses [75–79].
While the exact timing of the effects will vary by cell- and
radiation type, the universal effects such as the transient periods of
radiosensitivity and radioresistance are present in every tumour
and should subsequently be further studied within in vitro
experiments. Variation of cell parameters such as quiescence
radiation resistance, damage dynamics parameters, cell death
durations and quiescence criterion led to minor quantitative
changes, but the qualitative finding of transient radioresistant and
radio-sensitive periods was conserved. The readiness of cells to
enter and leave quiescence is of special interest, as it can increase
the dampening of the oscillatory response in enhancement.
Furthermore, the cell cycle duration and its typical variation are
important for the sensitivity timing. Even for high variations of the
typical cycle durations, which has been assumed in the simulation,
the enhancement effects were pronounced and could be used for
treatment optimisation. The specific nature of cell cycle check-
point regulations (or the loss of it) and their genomic basis were
disregarded in the present model. If a particular cell line is under
consideration the status of key regulatory genes such as TP53 or
ATM can be taken into consideration for refinement of the cell
behaviour within the model [80].
The presented model rests on a foundation of very basic
assumptions for the radiation reaction which are justified in most
cells: first, cells exhibit a variation in radiosensitivity between
different cell cycle phases [81], second, cells are subject to a degree
of cell cycle regulation in response to damage or due to
environmental effects (such as oxygenation, nutrient support or
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resistance to radiation [83]. Ergo the described cell cycle effect
should be present in any tumour system in which these
assumptions are justified, irrespective of cell type or composition,
although they may overlap or even be completely masked by other
effects, e.g. reoxygenation dynamics.
Considering the overall development of radiosensitivity in a
tumour which is triggered by irradiation, it seems reasonable to
apply a scheme of trigger- and follow-up-doses to exploit the
induced dynamics as was proposed and tested. Protocols which use
a small trigger dose followed by a larger effector dose aimed at
periods of high sensitivity could in principle be used clinically
without alteration of the overall dose-rate. However, the
identification of the transient periods of increased radiosensitivity
is mandatory, as a wrong timing could result in a decrease of
efficiency. When a multi-fractionated regimen is applied, the
timing of irradiation cannot be simply derived from the sensitivity
development in response to a single irradiation dose. Instead the
development of sensitivity will be more complex, as the internal
dynamics of the tumour (especially reactivation and depletion of
quiescent cells) play an important role. With the use of simple
automatic enhancement-based scheduling algorithms a significant
increase in treatment performance was achieved. Triggering based
on the monitoring of cell cycle-based enhancement is thus a
possible method to automatically design optimised schedules. Such
schedules would be robust as they can adapt to dynamic changes
of the tumour and would furthermore be largely independent of
any undetermined tumour parameters. In order to use any
optimised scheduling approaches, the identification of high and
low-enhancement periods is mandatory. Thus, live monitoring, or
at least a higher sampling frequency combined with a model for
the periods in between two measurements, is required to allow for
a stable exploitation of the potential of cell cycle synchronisation
effects.
While a higher frequency of monitoring induces additional
clinical workload it is in principle simple to achieve, especially with
combined PET/CT installations which are increasingly available
at clinical treatment sites. A higher imaging frequency is also called
for in conjunction with related phenomena such as hypoxia
dynamics [84], where it has been shown that temporal variations
of pO2 in mouse models exhibit 18-fold fluctuations with patterns
on the scale of only minutes [85]. This observation clearly
illustrates that measuring key tumour attributes only once or twice
during a prolonged therapy regimen is not sufficient to understand
or even therapeutically employ the kinetics of cell cycle
redistribution or reoxygenation.
Figure 6. Performance of specific triggered irradiation schedules. Protocols were designed to induce a cell cycle response in the tumour
which can be exploited in follow-up irradiations. A The overall reduction in tumour size achieved by different conventional and triggered schedules,
which consist of trigger- and effector-dose followed by a pause to achieve a constant dose per time interval of 2 Gy/24 h. The performance of other
triggered schedules can be found in the supplementary material figure S5. B Automatic triggering with a minimal inter-fraction time of tmin and a
minimal dose of Dmin compared to full manual optimal triggering. C Example of a stable and unstable repeated sensitivity development in A. D
Enhancement during automatic and full manual triggering in B (radiation timing marks omitted for visibility).
doi:10.1371/journal.pcbi.1003295.g006
Cell Cycle Synchronisation Effects in Radiotherapy
PLOS Computational Biology | www.ploscompbiol.org 11 November 2013 | Volume 9 | Issue 11 | e1003295An experimentally or even clinically accessible observable for
the synchronisation of the cell population is thus of utmost
importance and should be the target of future investigations. If the
orderedness of the cell cycle distribution can be assessed, its
correlation with the radiosensitivity enhancement could be used to
predict optimal irradiation times (see supporting figure S1).
Another approach could be the monitoring of oxygen or glucose
uptake in the tumour with high temporal resolution, as is regularly
called for in the context of hypoxia [84]. This uptake is related to
the collective development of the cycle distribution and therefore
the overall radiosensitivity. In the best case a continuous
monitoring of vital parameters such as cell cycle durations, key
gene expressions and so forth would be available by a combination
of imaging and possibly also sequential biopsies in order to predict
suitable irradiation intervals.
In summary this suggests a basic scheme for the inclusion of cell
cycle effects in therapy. In a first step the degree of cell cycle
redistributioninthetumourwhichoccurs inresponseto a treatment
should be assessed. This assessment can also take into account a
known genetic profile for cycle regulation and deregulation in the
tumour. If the tumour is found to be susceptible to cell cycle
redistribution and regulation, a synchronisation-based fractionation
scheme should be considered [71]. The prediction of radiation
sensitivity timings can thus be achieved using a basis of simulations
and monitoring or biopsies with cultures of primary tissue. In the
ideal case a feedback between modelling and measuring can be
achieved, where information from only a few biopsies will be
combined with a model in order to predict suitable patient-specific
irradiation timings.
Supporting Information
Figure S1 Correlated development of orderedness and
enhancement during tumour growth and irradiation. In
response to irradiation with 4 Gy at day 14 enhancement is
strongly correlated with orderedness. If the orderedness of the cell
population can be assessed experimentally, it can be used for the
prediction of radiosensitive time windows.
(TIF)
Figure S2 Radiation survival used within the simula-
tion. Cell-cycle phase specific survival data for V79 Chinese
hamster cells has been used as example for radiation survival in
this simulation [2]. A Survival curves include the average survival
of cells in S-phase, survival of radio-resistant quiescent cells (using
an effective dose reduction by a factor of 1.5 which follows
measurements by [47]), and the expected survival Sexp for the
weighted cell cycle times from EMT6 cells used for calculation of
the enhancement E. The spread in between survival of
radioresistant S-phase cells and sensitive M-phase cells grows
larger with increased dose, which is reflected in a higher possible
variation of the enhancement E as illustrated in panel B.
(TIF)
Figure S3 Comparison of spheroid growth and histolo-
gy in silico and in vitro. Growth of EMT6/Ro cells as
spheroids under different nutrient conditions was used to validate
the model and is shown in panel A in comparison to experimental
results from [43]. Panel B shows a thin central cutslice of a typical
spheroid with an outer actively proliferating rim, an intermediate
layer which is rich in quiescent cells and a hollow necrotic core
partially consisting only of cell debris. Scale bar size in the figure is
100mm. Qualitative equality of the in silico and in vitro spheroids can
be verified by comparison of the cutsection to experimental results
such as the one presented in [92], figure 2.
(TIF)
Figure S4 Visualisation of a tumour spheroid at differ-
ent times during a hypofractionated schedule. The
spheroid was seeded at 0 h using 10 cells and grew undisturbed
for 336 hours (upper row). Upon commencement of a high dose-
per-fraction treatment of 4 Gy/24 h a destruction of the spheroid
integrity through the dissolution of apoptotic cells was observed
which led to the subsequent formation of smaller cell aggregates
(middle row). In a stirred liquid medium the spheroid would
accordingly dissolve. The last dose of the schedule is applied at
768 h after which cessation of treatment led to a fast regrowth of
the tumour spheroid (bottom row).
(TIF)
Figure S5 Triggered schedules and the development of
enhancement. A Radiation schedules which applied a small
trigger dose in combination with a correctly timed effector
dose were in general more successful in tumour burden
reduction. The potential for synergy with an adjuvant
chemotherapy is high, especially for triggered schedules which
employ longer treatment pauses. B While a conventional 2
Gy/24 h schedule did not induce a persistent high enhance-
ment in the tumour the 2.5 Gy/30 h schedule led to an
increasing enhancement which was stable at a high level
throughout the whole regimen.
(TIF)
Figure S6 Timing of enhancement and dose delivery
can explain the nonlinear dependency between inter-
fraction time and number of fractions needed for
sterilisation. Enhancement details corresponding to the sched-
ules shown in figure 5. While an interval of 1000 min still results in
repeated delivery of the dose to a sensitive tumour a slightly
increased interval will lead to delivery within resistant time
windows. The associate change in total doses needed for
sterilisation of the tumour is considerable as seen in figure 5.
(TIF)
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